Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrew Baker

Physician Assistant, Surgical Columbus, OH Physician Assistant

NPI 1427318393 CMS profile 10536739

915 Olentangy River Rd, Suite 2100, Columbus, OH 43212

Open in the dashboard

General payments

$102,202

786 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Baker of Columbus, OH is reported in the CMS Open Payments database as having received $102,202 across 786 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,107 352
2024 General $25,072 163
2023 General $11,544 132
2022 General $1,551 79
2021 General $929 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Baker
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Andrew Baker were reported at $63,107. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Andrew Baker Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $929 $111 $36–$285 $132
2022 $1,551 $126 $44–$350 $149
2023 $11,544 $137 $47–$355 $160
2024 $25,072 $146 $49–$384 $164
2025 $63,107 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $23,334 94 payments
  2. Genzyme Corporation $13,978 51 payments
  3. E.R. Squibb & Sons, L.L.C. $12,787 53 payments
  4. Novartis Pharmaceuticals Corporation $11,374 62 payments
  5. Sun Pharmaceutical Industries Inc. $9,366 44 payments
  6. Incyte Corporation $8,031 44 payments
  7. Janssen Biotech, Inc. $6,498 62 payments
  8. Arcutis Biotherapeutics, Inc. $6,206 30 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $2,303 7 payments
  10. AbbVie, Inc. $2,184 149 payments
  11. Other $6,141 190 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $34,898 19 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,048 18 payments
  3. Travel and Lodging $18,434 49 payments
  4. Food and Beverage $16,300 690 payments
  5. Education $522 10 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology And Inflammation $15,165 40 payments
  2. DUPIXENT Immunology $14,117 61 payments
  3. SOTYKTU $9,069 45 payments
  4. DUPIXENT Inflammation And Immunology $7,939 38 payments
  5. OPZELURA $6,983 42 payments
  6. TREMFYA $6,567 63 payments
  7. Zoryve $4,932 11 payments
  8. Odomzo $4,872 15 payments
  9. COSENTYX $4,387 26 payments
  10. SPEVIGO $2,218 5 payments
  11. Other $9,729 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

489

Median for Physician Assistant: 241

Drug cost

$217,760

Median for Physician Assistant: $4,110

Branded share of claims

17%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 57 $209,202
Fluorouracil Generic 44 $3,954
Fluocinonide Generic 43 $2,229
Triamcinolone Acetonide Generic 90 $765
Ketoconazole Generic 29 $388
Doxycycline Hyclate Generic 42 $326
Mupirocin Generic 47 $286
Hydroxyzine Hcl Generic 29 $236
Azithromycin Generic 55 $209
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 26 $82

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$2,813

Medicare's payments for the services billed

Medicare patients

26

Average age 74

Services billed

89

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 62%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$12,650 57 —
OPZELURA
$1,415 — —
Zoryve
$340 — —
SOTYKTU
$315 — —
TREMFYA
$242 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

786 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record